Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

203.11 +7.09 (+3.62%)
Streaming Delayed Price Updated: 10:25 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off ↗
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
Via InvestorPlace
News headline image
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Ligand Reports First Quarter 2024 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Ligand Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach ↗
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... 
Via Talk Markets
News headline image
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
7 Small-Cap Stocks for the Thinking Speculator ↗
While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. 
Via InvestorPlace
News headline image
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Why Is Ligand Pharmaceuticals Stock Trading Higher Today? ↗
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. 
Via Benzinga
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
From Palvella Therapeutics
Via GlobeNewswire
News headline image
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's ↗
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
Via Benzinga
News headline image
Ligand Reports Third Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.